Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLV026
MIFTS: 60

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Salivary Gland Carcinoma

About this section

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 36 54 42 15
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Malignant Neoplasm of Salivary Gland 12
Major Salivary Gland Carcinoma 17

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 36 H01508
ICD9CM 34 142.8
ICD10 32 C08
UMLS 71 C0153362
Sources

Summaries for Salivary Gland Carcinoma

About this section
KEGG : 36 Salivary gland carcinomas are rare tumours representing about 0.5% of all malignancies and less than 5 % of all head and neck cancers. These are a heterogeneous group of tumors that include 24 histologically distinct tumor types. Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. The most common genetic alteration in MECs is a unique translocation t(11;19)(q21;p13) producing the MECT1-MAML2 fusion protein. This fusion transcript can activate transcription of targets in the Notch pathway. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) overexpression is present in a minority of MECs and is associated with higher rate of metastasis and worse overall survival. Recent studies have evaluated the epidermal growth factor receptor family including EGFR and HER2 as potential therapeutic targets.

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and pleomorphic adenoma. An important gene associated with Salivary Gland Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and ERK Signaling. The drugs Iodine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

MedlinePlus : 42 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

Sources

Related Diseases for Salivary Gland Carcinoma

About this section

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 33.3 SERPINA3 MAML2 EGFR CRTC1 CDKN2A
2 pleomorphic adenoma 31.6 MDM2 MAML2 CRTC1 CDKN2A
3 adenoid cystic carcinoma 31.5 SOX2 SERPINA3 MDM2 KIT EGFR CYLD
4 adenocarcinoma 31.4 MET MDM2 KIT HGF FGFR1 EGFR
5 pleomorphic adenoma carcinoma 31.3 MAML2 CRTC1
6 nasopharyngeal carcinoma 30.9 SOX2 MDM2 FGFR1 EGFR CDKN2A
7 mucinous adenocarcinoma 30.8 KIT EGFR CDKN2A
8 exanthem 30.7 KIT H2AC18 EGFR
9 basal cell carcinoma 30.7 SOX2 MDM2 KIT EGFR CYLD CDKN2A
10 breast secretory carcinoma 30.6 SERPINA3 MAML2
11 lymphoma 30.4 MET MDM2 KIT FGFR1 EGFR CDKN2A
12 lung cancer susceptibility 3 29.9 SOX2 SERPINA3 MET MDM2 KIT HGF
13 salivary gland disease 29.5 TST SERPINA3 NR4A1 MAML2 KIT ISL1
14 salivary gland cancer, adult 12.7
15 parotid gland cancer 11.6
16 cylindromatosis, familial 11.4
17 multiple familial trichoepithelioma 11.4
18 sublingual gland cancer 11.3
19 chronic erosive gastritis 10.7 MET HGF
20 mediastinum liposarcoma 10.7 MDM2 CDKN2A
21 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
22 esophagus verrucous carcinoma 10.7 MDM2 EGFR CDKN2A
23 cervical adenoid cystic carcinoma 10.7 KIT CDKN2A
24 verrucous carcinoma 10.7 MDM2 EGFR CDKN2A
25 heart leiomyosarcoma 10.7 MDM2 KIT CDKN2A
26 doxorubicin induced cardiomyopathy 10.7 MET HGF EGFR
27 vulvar disease 10.7 KIT EGFR CDKN2A
28 acral lentiginous melanoma 10.7 MET KIT CDKN2A
29 pleomorphic liposarcoma 10.7 MDM2 KIT CDKN2A
30 hypopharynx cancer 10.7 MET EGFR CDKN2A
31 gliomatosis cerebri 10.7 MDM2 EGFR CDKN2A
32 peritoneum cancer 10.7 EGFR CDKN2A BRCA1
33 mediastinum sarcoma 10.7 MDM2 CDKN2A
34 basaloid squamous cell carcinoma 10.7 SOX2 EGFR CDKN2A
35 peritoneal mesothelioma 10.7 MET EGFR CDKN2A
36 lacrimal gland mucoepidermoid carcinoma 10.7 MAML2 CRTC1
37 anus basaloid carcinoma 10.7 KIT CYLD CDKN2A
38 keratinizing squamous cell carcinoma 10.6 MAML2 EGFR CDKN2A
39 breast malignant phyllodes tumor 10.6 SERPINA3 KIT EGFR
40 inflammatory liposarcoma 10.6 MDM2 CDKN2A
41 fibrosarcoma of bone 10.6 SERPINA3 KIT CDKN2A
42 anal squamous cell carcinoma 10.6 MDM2 H2AC18 CDKN2A
43 embryonal sarcoma 10.6 SERPINA3 MDM2 KIT
44 cutaneous solitary mastocytoma 10.6 SERPINA3 KIT
45 mesenchymoma 10.6 SERPINA3 MDM2 KIT
46 undifferentiated embryonal sarcoma of the liver 10.6 SERPINA3 MDM2
47 fibrillary astrocytoma 10.6 H2AC18 EGFR CDKN2A
48 heart cancer 10.6 SERPINA3 MDM2 KIT
49 cutaneous mucoepidermoid carcinoma 10.6 MAML2 CRTC1
50 respiratory system benign neoplasm 10.6 H2AC18 EGFR CDKN2A

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma
Sources

Symptoms & Phenotypes for Salivary Gland Carcinoma

About this section

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

26 (show all 43)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.05 EGFR
2 Decreased viability GR00221-A-1 10.05 CDKN2A CYLD EGFR FGFR1 HGF KIT
3 Decreased viability GR00221-A-2 10.05 CYLD FGFR1 HGF
4 Decreased viability GR00221-A-3 10.05 CDKN2A
5 Decreased viability GR00221-A-4 10.05 CDKN2A EGFR HGF SOX2
6 Decreased viability GR00301-A 10.05 CYLD KIT
7 Decreased viability GR00402-S-2 10.05 CDKN2A CYLD EGFR FGFR1 HGF KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.91 FGFR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.91 H2AC18
10 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.91 EGFR MDM2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.91 EGFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.91 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.91 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.91 BRCA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.91 MDM2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.91 BRCA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.91 MDM2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.91 MDM2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.91 BRCA1 H2AC18
20 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.91 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.91 MDM2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.91 FGFR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.91 BRCA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.91 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.91 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.91 BRCA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.91 MDM2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.91 FGFR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.91 BRCA1 EGFR FGFR1 H2AC18 MDM2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.91 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 BRCA1 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.91 MDM2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.91 BRCA1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.91 FGFR1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.91 H2AC18
37 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.91 FGFR1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 EGFR
39 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.91 H2AC18
40 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT MET
41 Decreased substrate adherent cell growth GR00193-A-2 9.7 KIT
42 Decreased substrate adherent cell growth GR00193-A-3 9.7 MET
43 Decreased substrate adherent cell growth GR00193-A-4 9.7 FGFR1 KIT MET

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 ACTN4 BRCA1 CDKN2A EGFR FGFR1 HGF
2 endocrine/exocrine gland MP:0005379 10.46 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
3 cellular MP:0005384 10.42 ACTN4 BRCA1 CDKN2A CYLD EGFR FGFR1
4 growth/size/body region MP:0005378 10.42 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
5 immune system MP:0005387 10.38 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
6 embryo MP:0005380 10.37 ACTN4 BRCA1 CDKN2A EGFR FGFR1 HGF
7 hematopoietic system MP:0005397 10.37 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
8 homeostasis/metabolism MP:0005376 10.36 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
9 digestive/alimentary MP:0005381 10.34 ACTN4 BRCA1 CDKN2A CYLD EGFR FGFR1
10 mortality/aging MP:0010768 10.32 ACTN4 BRCA1 CDKN2A CYLD EGFR FGFR1
11 integument MP:0010771 10.22 BRCA1 CDKN2A CYLD EGFR FGFR1 ISL1
12 craniofacial MP:0005382 10.21 ACTN4 EGFR FGFR1 ISL1 KIT MDM2
13 muscle MP:0005369 10.2 ACTN4 BRCA1 CDKN2A EGFR FGFR1 ISL1
14 neoplasm MP:0002006 10.17 ACTN4 BRCA1 CDKN2A CYLD EGFR ISL1
15 nervous system MP:0003631 10.14 ACTN4 BRCA1 CDKN2A EGFR FGFR1 ISL1
16 limbs/digits/tail MP:0005371 10.11 BRCA1 CYLD EGFR FGFR1 ISL1 KIT
17 liver/biliary system MP:0005370 10.1 ACTN4 CDKN2A EGFR HGF KIT MDM2
18 normal MP:0002873 10.06 BRCA1 CYLD EGFR FGFR1 ISL1 KIT
19 hearing/vestibular/ear MP:0005377 10.04 ACTN4 EGFR FGFR1 ISL1 KIT SOX2
20 no phenotypic analysis MP:0003012 10.02 CDKN2A EGFR FGFR1 HGF ISL1 KIT
21 renal/urinary system MP:0005367 9.81 ACTN4 BRCA1 EGFR FGFR1 ISL1 KIT
22 pigmentation MP:0001186 9.73 BRCA1 CDKN2A EGFR KIT MDM2 SOX2
23 reproductive system MP:0005389 9.7 BRCA1 CDKN2A CRTC1 EGFR FGFR1 ISL1
24 respiratory system MP:0005388 9.23 ACTN4 BRCA1 CDKN2A CYLD EGFR KIT
Sources

Drugs & Therapeutics for Salivary Gland Carcinoma

About this section

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
leucovorin Approved Phase 3 58-05-9 6006 143
6
Histamine Approved, Investigational Phase 3 51-45-6 774
7
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
8
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
9
Promethazine Approved, Investigational Phase 3 60-87-7 4927
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
14 cadexomer iodine Phase 3
15 Liver Extracts Phase 3
16 Cola Phase 3
17 Neurotransmitter Agents Phase 3
18 Muscarinic Agonists Phase 3
19 Autonomic Agents Phase 3
20 Cholinergic Agents Phase 3
21 Analgesics Phase 3
22 Folic Acid Antagonists Phase 3
23 Vitamin B Complex Phase 3
24 Dermatologic Agents Phase 3
25 Vitamin B9 Phase 3
26 Folate Phase 3
27 Hypnotics and Sedatives Phase 3
28 Psychotropic Drugs Phase 3
29 Histamine Antagonists Phase 3
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Antidepressive Agents Phase 3
32 Central Nervous System Depressants Phase 3
33 Antidepressive Agents, Tricyclic Phase 3
34 Narcotics Phase 3
35 Anesthetics Phase 3
36 Anesthetics, General Phase 3
37 Analgesics, Opioid Phase 3
38 Adjuvants, Anesthesia Phase 3
39 Anesthetics, Intravenous Phase 3
40
Nintedanib Approved Phase 2 656247-17-5 56843413
41
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
42
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
43
Racepinephrine Approved Phase 2 329-65-7 838
44
Temoporfin Approved, Investigational Phase 2 122341-38-2
45
Indinavir Approved Phase 2 150378-17-9 5362440
46
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Gemcitabine Approved Phase 2 95058-81-4 60750
49
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
50
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
2 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
3 A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors Unknown status NCT01216800 Phase 3
4 A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients Completed NCT00021125 Phase 3
5 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00003592 Phase 3 methotrexate;paclitaxel
7 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
8 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
9 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
11 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
12 Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study Unknown status NCT02558387 Phase 2 BIBF1120
13 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
14 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
15 A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
16 A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy Unknown status NCT00003856 Phase 2 temoporfin
17 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study Completed NCT01703455 Phase 2 Sorafenib
19 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
20 PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES Completed NCT00002632 Phase 2 paclitaxel
21 Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers Completed NCT01613768 Phase 2 eribulin mesylate
22 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
23 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
24 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
25 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Completed NCT02393820 Phase 2 pazopanib
26 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
27 Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck Completed NCT00559156 Phase 2 cisplatin
28 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
29 Pilot Study of the Relationship Between EF5 Uptake and Concentration of Oxygen-Related Metabolites in Head and Neck Cancer Completed NCT00049140 Phase 2 EF5
30 Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck Completed NCT00738868 Phase 2
31 Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00057850 Phase 1, Phase 2 cisplatin;ixabepilone
32 Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma Completed NCT00040807 Phase 2 docetaxel;irinotecan hydrochloride
33 A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00020189 Phase 2 acetylsalicylic acid;alvocidib;clopidogrel bisulfate
34 Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck Completed NCT00003264 Phase 2 cisplatin;gemcitabine hydrochloride
35 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
36 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
37 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
38 Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers Completed NCT00058006 Phase 2 celecoxib
39 Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
40 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
41 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
42 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
43 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
44 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
45 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
46 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
47 Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung Completed NCT00021333 Phase 2 cisplatin;paclitaxel
48 Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
49 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
50 A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab

Search NIH Clinical Center for Salivary Gland Carcinoma

Sources

Genetic Tests for Salivary Gland Carcinoma

About this section
Sources

Anatomical Context for Salivary Gland Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

19
Salivary Gland

MalaCards organs/tissues related to Salivary Gland Carcinoma:

40
Salivary Gland, Breast, Lung, Thyroid, Testes, Lymph Node, Skin
Sources

Publications for Salivary Gland Carcinoma

About this section

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 638)
# Title Authors PMID Year
1
The evolution of nasopharyngeal carcinoma staging. 42
31298937 2019
2
Parotid gland carcinoma: 32 years' experience from a single institute. 42
31169091 2019
3
Parotid carcinoma and adjunct radiation therapy and the case for combined approach in paediatric antrochoanal surgery. 42
31423960 2019
4
CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. 54 61
19159612 2009
5
Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. 54 61
18355439 2008
6
Expression and cellular localization of TSC-22 in normal salivary glands and salivary gland tumors: implications for tumor cell differentiation. 54 61
18288391 2008
7
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. 54 61
16469527 2006
8
CD151 forms a functional complex with c-Met in human salivary gland cancer cells. 54 61
16139245 2005
9
TSC-22 (TGF-beta stimulated clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. 54 61
15379637 2004
10
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. 54 61
13679209 2003
11
Cytoplasmic TSC-22 (transforming growth factor-beta-stimulated clone-22) markedly enhances the radiation sensitivity of salivary gland cancer cells. 54 61
11944908 2002
12
Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. 54 61
11836575 2002
13
Leucine zipper structure of TSC-22 (TGF-beta stimulated clone-22) markedly inhibits the anchorage-independent growth of salivary gland cancer cells. 54 61
11836610 2002
14
In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. 54 61
10854535 2000
15
Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. 54 61
10879745 2000
16
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. 54 61
9458104 1998
17
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. 54 61
9459148 1998
18
Optimal Treatment for the High-Risk Salivary Gland Cancer. 61
32036639 2020
19
Nivolumab in patients with rare head and neck carcinomas: A single center's experience. 61
31300270 2020
20
Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma. 61
31959347 2020
21
A retrospective multicenter study of sublingual gland carcinoma in Japan. 61
31104870 2020
22
Clinical outcome and comparison between squamous and non-squamous cell carcinoma of the larynx. 61
31852360 2020
23
Prognostic value of lymph node density for major salivary gland carcinoma without clinical lymph node metastasis. 61
31727336 2020
24
[Salivary gland malignancies-highlights of the 2019 ASCO Annual Meeting]. 61
31628530 2019
25
Minimal acute toxicity from proton beam therapy for major salivary gland cancer. 61
31805791 2019
26
Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer. 61
31511971 2019
27
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. 61
31796519 2019
28
Advances and challenges in precision medicine in salivary gland cancer. 61
31644971 2019
29
Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. 61
31430492 2019
30
Large Population Analysis of Secondary Cancers in Pediatric Leukemia Survivors. 61
31795500 2019
31
Anatomic extent of lymph node metastases as an independent prognosticator in node-positive major salivary gland carcinoma: A study of the US SEER database and a Chinese multicenter cohort. 61
31253544 2019
32
Next-generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage-Multicenter experience. 61
31762146 2019
33
Peripheral T Cell Lymphoma of Parotid Gland: A Diagnostic Challenge. 61
31742016 2019
34
Salivary ghost cell carcinoma: case report and proposal of a new entity. 61
31616980 2019
35
Impact of treating facilities' type and volume in patients with major salivary gland cancer. 61
30698823 2019
36
Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study. 61
30673867 2019
37
The expression of PD-L1 in salivary gland carcinomas. 61
31484986 2019
38
Texture analysis of pretreatment [18F]FDG PET/CT for the prognostic prediction of locally advanced salivary gland carcinoma treated with interstitial brachytherapy. 61
31511990 2019
39
Prognostic markers in salivary gland cancer and their impact on survival. 61
31246357 2019
40
Multicenter study of carbon-ion radiation therapy for nonsquamous cell carcinomas of the oral cavity. 61
31369213 2019
41
Assessment of salivary endothelin-1 in patients with leukoplakia, submucous fibrosis, oral cancer and healthy individuals - a comparative study. 61
30858129 2019
42
Radiation-Related Risk of Cancers of the Upper Digestive Tract among Japanese Atomic Bomb Survivors. 61
31356146 2019
43
The role of elective neck dissection in patients with adenoid cystic carcinoma of the head and neck. 61
30667061 2019
44
Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. 61
31423558 2019
45
Up-front F18-FDG PET/CT in suspected salivary gland carcinoma. 61
31102059 2019
46
HPV-Related Multiphenotypic Sinonasal Carcinoma: A Unique Case. 61
31405309 2019
47
Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer. 61
30905082 2019
48
Correlation of apparent diffusion coefficient with histopathological parameters of salivary gland cancer. 61
30975578 2019
49
Predictors for Salivary Gland Cancer Recurrence at Two Tertiary Hospitals in Saudi Arabia. 61
31576277 2019
50
The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: Results from the surveillance, epidemiology, and End Results dataset. 61
30472214 2019
Sources

Variations for Salivary Gland Carcinoma

About this section

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 1335)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 48
2 COSM105721467 salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 48
3 COSM97921670 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 48
4 COSM133255277 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.117A>C p.K39N 9:99129081-99129081 48
5 COSM97906020 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 48
6 COSM149281700 ZFHX3 salivary gland,major,carcinoma,NS c.8617G>A p.E2873K 16:72794065-72794065 36
7 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 36
8 COSM131095467 TSHR salivary gland,major,carcinoma,NS c.1376C>T p.A459V 14:81143434-81143434 36
9 COSM87031764 TSC2 salivary gland,major,carcinoma,NS c.2276G>A p.R759K 16:2072904-2072904 36
10 COSM87028709 TSC2 salivary gland,major,carcinoma,NS c.2402C>T p.A801V 16:2074246-2074246 36
11 COSM85719495 TSC1 salivary gland,major,carcinoma,NS c.2684T>A p.V895D 9:132897552-132897552 36
12 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 36
13 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 36
14 COSM88223810 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 36
15 COSM87899785 TP53 salivary gland,major,carcinoma,NS c.991C>T p.Q331* 17:7673537-7673537 36
16 COSM87898351 TP53 salivary gland,major,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 36
17 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 36
18 COSM88218639 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 36
19 COSM87947300 TP53 salivary gland,major,carcinoma,NS c.96+1G>T p.? 17:7676381-7676381 36
20 COSM87899497 TP53 salivary gland,major,carcinoma,NS c.586C>T p.R196* 17:7674945-7674945 36
21 COSM87961733 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 36
22 COSM87925450 TP53 salivary gland,major,carcinoma,NS c.523C>A p.R175S 17:7675089-7675089 36
23 COSM87897883 TP53 salivary gland,major,carcinoma,NS c.659A>G p.Y220C 17:7674872-7674872 36
24 COSM88043721 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 17:7675062-7675062 36
25 COSM87910752 TP53 salivary gland,major,carcinoma,NS c.949C>T p.Q317* 17:7673579-7673579 36
26 COSM87905856 TP53 salivary gland,major,carcinoma,NS c.643A>G p.S215G 17:7674888-7674888 36
27 COSM87900273 TP53 salivary gland,major,carcinoma,NS c.427G>A p.V143M 17:7675185-7675185 36
28 COSM87897745 TP53 salivary gland,major,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 36
29 COSM87898723 TP53 salivary gland,major,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 36
30 COSM87933369 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 36
31 COSM88075150 TP53 salivary gland,major,carcinoma,NS c.483C>T p.A161= 17:7675129-7675129 36
32 COSM87898431 TP53 salivary gland,major,carcinoma,NS c.451C>T p.P151S 17:7675161-7675161 36
33 COSM87899695 TP53 salivary gland,major,carcinoma,NS c.715A>G p.N239D 17:7674248-7674248 36
34 COSM87912247 TP53 salivary gland,major,carcinoma,NS c.523C>T p.R175C 17:7675089-7675089 36
35 COSM87901886 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 36
36 COSM88420642 THRA salivary gland,mouth floor,carcinoma,NS c.1162C>T p.R388W 17:40093071-40093071 36
37 COSM96853830 TENT5C salivary gland,major,carcinoma,NS c.702G>C p.K234N 1:117623570-117623570 36
38 COSM96852092 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 36
39 COSM85452528 TCF3 salivary gland,major,carcinoma,NS c.173C>T p.S58F 19:1632378-1632378 36
40 COSM92119498 SUZ12 salivary gland,major,carcinoma,NS c.766C>T p.R256C 17:31975656-31975656 36
41 COSM96394806 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 36
42 COSM86749613 STAG2 salivary gland,major,carcinoma,NS c.2405T>G p.I802S 23:124071195-124071195 36
43 COSM86759076 STAG2 salivary gland,major,carcinoma,NS c.1808G>A p.G603E 23:124063192-124063192 36
44 COSM99809024 SPEN salivary gland,major,carcinoma,NS c.1648C>T p.R550C 1:15920882-15920882 36
45 COSM88093366 SOX9 salivary gland,major,carcinoma,NS c.1457T>A p.V486D 17:72124314-72124314 36
46 COSM84585112 SOX17 salivary gland,major,carcinoma,NS c.1181C>T p.A394V 8:54459931-54459931 36
47 COSM84674496 SMO salivary gland,major,carcinoma,NS c.385G>C p.V129L 7:129203437-129203437 36
48 COSM84673917 SMO salivary gland,major,carcinoma,NS c.1513C>T p.P505S 7:129210409-129210409 36
49 COSM89651491 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 36
50 COSM89665843 SMARCA4 salivary gland,major,carcinoma,NS c.848C>G p.P283R 19:10986992-10986992 36
Sources

Expression for Salivary Gland Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Carcinoma.
Sources

Pathways for Salivary Gland Carcinoma

About this section

Pathways related to Salivary Gland Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.73 SOX2 MET MDM2 KIT HGF FGFR1
2
Phospholipase-C Pathway 63
Show member pathways
 12.99 MET MDM2 KIT HGF FGFR1 EGFR
3
GAB1 signalosome 65
Show member pathways
 12.97 NR4A1 MET MDM2 KIT HGF FGFR1
4
Ras signaling pathway 36
Show member pathways
 12.65 MET KIT HGF FGFR1 EGFR
5
MAPK signaling pathway 36 1
12.6 NR4A1 MET KIT HGF FGFR1 EGFR
6
Pathways in cancer 36
12.59 MET MDM2 KIT HGF FGFR1 EGFR
7
Gastric cancer 36
Show member pathways
 12.47 MET KIT HGF FGFR1 EGFR CDKN2A
8
MicroRNAs in cancer 36
12.44 MET MDM2 EGFR CDKN2A BRCA1
9
Apoptosis Pathway 70
Show member pathways
 12.36 MET MDM2 FGFR1 EGFR
10
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.34 NR4A1 MET MDM2 KIT HGF FGFR1
11
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.33 MET KIT HGF FGFR1 EGFR
12
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.2 MET KIT HGF FGFR1 EGFR
13
Proteoglycans in cancer 36
12.14 MET MDM2 HGF FGFR1 EGFR
14
PI3K-Akt signaling pathway 36
Show member pathways
 12.11 NR4A1 MET MDM2 MAML2 KIT HGF
15
Glioma 36
Show member pathways
 12.1 MET MDM2 HGF FGFR1 EGFR CDKN2A
16
Tyrosine Kinases / Adaptors 4
12.06 MET KIT FGFR1 EGFR
17
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.96 SOX2 MET ISL1 HGF
18
Direct p53 effectors 1
11.95 MET MDM2 HGF EGFR
19
Listeria monocytogenes entry into host cells 65
Show member pathways
 11.79 MET HGF EGFR
20
Androgen receptor signaling pathway 1
11.78 MDM2 EGFR BRCA1
21
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.71 SOX2 ISL1 FGFR1
22
Platinum drug resistance 36
11.67 MDM2 CDKN2A BRCA1
23
Bladder cancer 36 1
11.66 MDM2 EGFR CDKN2A
24
Adherens junction 36
11.56 MET FGFR1 EGFR ACTN4
25
Cardiac Progenitor Differentiation 1
11.51 SOX2 KIT ISL1
26
Central carbon metabolism in cancer 36
11.51 MET KIT FGFR1 EGFR
27
FGF signaling pathway 1
11.45 MET HGF FGFR1
28
Signaling events mediated by TCPTP 1
Show member pathways
 11.38 MET HGF EGFR
29
Stabilization and expansion of the E-cadherin adherens junction 1
11.35 MET HGF EGFR
30
Arf6 signaling events 1
11.22 MET HGF EGFR
31
Extracellular vesicle-mediated signaling in recipient cells 1
11.13 MET HGF EGFR
Sources

GO Terms for Salivary Gland Carcinoma

About this section

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.1 TSC22D1 SPHK1 SOX2 NR4A1 MDM2 KIT
2 nucleus GO:0005634 9.5 TSC22D1 SPHK1 SOX2 SERPINA3 NR4A1 MDM2
3 platelet alpha granule lumen GO:0031093 9.33 SERPINA3 HGF ACTN4
4 receptor complex GO:0043235 9.26 MET KIT FGFR1 EGFR

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10 SPHK1 MET KIT FGFR1 EGFR CDKN2A
2 regulation of gene expression GO:0010468 9.9 SOX2 MDM2 ISL1 FGFR1
3 regulation of cell proliferation GO:0042127 9.86 KIT FGFR1 EGFR BRCA1
4 positive regulation of cell proliferation GO:0008284 9.85 SPHK1 MDM2 KIT ISL1 FGFR1 EGFR
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 KIT HGF FGFR1
6 positive regulation of angiogenesis GO:0045766 9.8 SPHK1 ISL1 HGF BRCA1
7 liver development GO:0001889 9.78 MET HGF EGFR
8 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.74 NR4A1 MDM2 HGF
9 positive regulation of MAP kinase activity GO:0043406 9.72 KIT FGFR1 EGFR
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.71 SPHK1 EGFR ACTN4
11 peptidyl-tyrosine phosphorylation GO:0018108 9.71 MET KIT FGFR1 EGFR
12 positive regulation of cell differentiation GO:0045597 9.69 SOX2 ISL1 FGFR1
13 MAPK cascade GO:0000165 9.65 MET KIT HGF FGFR1 EGFR
14 positive regulation of phospholipase C activity GO:0010863 9.63 KIT FGFR1
15 amyloid fibril formation GO:1990000 9.62 MDM2 CDKN2A
16 hepatocyte growth factor receptor signaling pathway GO:0048012 9.62 MET HGF
17 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 MET KIT FGFR1 EGFR
18 tongue development GO:0043586 9.61 KIT EGFR
19 mesenchymal cell differentiation GO:0048762 9.59 ISL1 FGFR1
20 somatic stem cell division GO:0048103 9.58 KIT CDKN2A
21 salivary gland morphogenesis GO:0007435 9.58 FGFR1 EGFR
22 positive regulation of cell migration GO:0030335 9.55 SPHK1 KIT HGF EGFR ACTN4
23 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.48 MET HGF
24 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.46 HGF FGFR1
25 chordate embryonic development GO:0043009 9.43 FGFR1 BRCA1
26 positive regulation of protein kinase B signaling GO:0051897 9.35 MET KIT HGF FGFR1 EGFR
27 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 SOX2 NR4A1 MET MAML2 ISL1 HGF

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.92 TST SPHK1 MET MDM2 KIT FGFR1
2 kinase activity GO:0016301 9.63 SPHK1 MET KIT FGFR1 EGFR CDKN2A
3 5S rRNA binding GO:0008097 9.26 TST MDM2
4 protein tyrosine kinase activity GO:0004713 9.26 MET KIT FGFR1 EGFR
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 MET KIT FGFR1 EGFR
Sources

Sources for Salivary Gland Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....